334 related articles for article (PubMed ID: 35348553)
21. Qualimetric analysis of proton pump inhibitors in Ukraine.
Makarenko OV; Karimova MM; Masheiko AM; Onul NM
Wiad Lek; 2019; 72(9 cz 2):1769-1773. PubMed ID: 31622264
[TBL] [Abstract][Full Text] [Related]
22. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
Arbel Y; Birati EY; Finkelstein A; Halkin A; Kletzel H; Abramowitz Y; Berliner S; Deutsch V; Herz I; Keren G; Banai S
Clin Cardiol; 2013 Jun; 36(6):342-6. PubMed ID: 23630016
[TBL] [Abstract][Full Text] [Related]
23. Proton Pump Inhibitors Inhibit PHOSPHO1 Activity and Matrix Mineralisation In Vitro.
Staines KA; Myers K; Little K; Ralston SH; Farquharson C
Calcif Tissue Int; 2021 Dec; 109(6):696-705. PubMed ID: 34213594
[TBL] [Abstract][Full Text] [Related]
24. A fixed-dose combination ibuprofen and famotidine (Duexis).
Med Lett Drugs Ther; 2011 Oct; 53(1376):85-6. PubMed ID: 22033211
[TBL] [Abstract][Full Text] [Related]
25. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
27. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
28. Formulary management of proton pump inhibitors.
Byrne MF; Murray FE
Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
30. Combination drug therapy for gastroesophageal reflux disease.
Cross LB; Justice LN
Ann Pharmacother; 2002 May; 36(5):912-6. PubMed ID: 11978171
[TBL] [Abstract][Full Text] [Related]
31. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Haga Y; Nakatsura T; Shibata Y; Sameshima H; Nakamura Y; Tanimura M; Ogawa M
Dig Dis Sci; 1998 Feb; 43(2):253-7. PubMed ID: 9512115
[No Abstract] [Full Text] [Related]
32. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
[TBL] [Abstract][Full Text] [Related]
33. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
34. In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Gebhardt E; Eberlein B; Przybilla B; Gilbertz KP; Placzek M
Acta Derm Venereol; 2012 Mar; 92(2):208-10. PubMed ID: 22002635
[No Abstract] [Full Text] [Related]
35. Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study.
Chen WC; Li YD; Chiang PH; Tsay FW; Chan HH; Tsai WL; Tsai TJ; Wang EM; Cheng JS; Lai KH
Biomed Res Int; 2014; 2014():693567. PubMed ID: 25295267
[TBL] [Abstract][Full Text] [Related]
36. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Xue S; Katz PO; Banerjee P; Tutuian R; Castell DO
Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Hong EJ; Park DI; Oh SJ; Song MJ; Choi WH; Hong CH; Park JH; Kim HJ; Cho YK; Shon CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2008 Aug; 52(2):80-5. PubMed ID: 19077498
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
39. Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.
Zacny J; Zamakhshary M; Sketris I; Veldhuyzen van Zanten S
Aliment Pharmacol Ther; 2005 Jun; 21(11):1299-312. PubMed ID: 15932360
[TBL] [Abstract][Full Text] [Related]
40. The changing role of H2-receptor antagonists in acid-related diseases.
Lamers CB
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S3-7. PubMed ID: 8930573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
